These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38581551)
21. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage. Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462 [TBL] [Abstract][Full Text] [Related]
22. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Yasaka M; Sakata T; Naritomi H; Minematsu K Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675 [TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal. Voils SA; Holder MC; Premraj S; Catlin JR; Allen BR Thromb Res; 2015 Sep; 136(3):595-8. PubMed ID: 26233569 [TBL] [Abstract][Full Text] [Related]
24. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0. Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341 [TBL] [Abstract][Full Text] [Related]
25. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690 [TBL] [Abstract][Full Text] [Related]
26. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding. Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715 [TBL] [Abstract][Full Text] [Related]
27. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa. Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317 [TBL] [Abstract][Full Text] [Related]
28. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580 [TBL] [Abstract][Full Text] [Related]
29. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage. Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162 [TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage. Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286 [TBL] [Abstract][Full Text] [Related]
31. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy. Huynh TK; Costello JL; Rebuck JA Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal. Stoecker Z; Van Amber B; Woster C; Isenberger K; Peterson M; Rupp P; Chrenka E; Dries D Am J Emerg Med; 2021 Oct; 48():282-287. PubMed ID: 34022636 [TBL] [Abstract][Full Text] [Related]
33. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding. Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage. Scott R; Kersten B; Basior J; Nadler M J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892 [TBL] [Abstract][Full Text] [Related]
35. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal. Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496 [TBL] [Abstract][Full Text] [Related]
36. Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal. Rowe AS; Dietrich SK; Phillips JW; Foster KE; Canter JR Crit Care Med; 2018 Jun; 46(6):943-948. PubMed ID: 29498942 [TBL] [Abstract][Full Text] [Related]
37. Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience. Mačiukaitienė J; Bilskienė D; Tamašauskas A; Bunevičius A Medicina (Kaunas); 2018 Apr; 54(2):. PubMed ID: 30344253 [No Abstract] [Full Text] [Related]
38. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis. Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728 [TBL] [Abstract][Full Text] [Related]
39. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa". Van Dusen R Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484 [TBL] [Abstract][Full Text] [Related]
40. 3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study. Jones GM; Erdman MJ; Smetana KS; Mohrien KM; Vandigo JE; Elijovich L J Thromb Thrombolysis; 2016 Jul; 42(1):19-26. PubMed ID: 26721625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]